Doctors report the case of a 45-year-old man who had fatigue, anemia, clubbed fingers, and thickened skin. He was found to have a rare genetic condition called primary hypertrophic osteoarthropathy (PHO). Whole-exome sequencing showed he had two mutations in the SLCO2A1 gene. Further testing revealed he also had myelofibrosis, a type of blood cancer. This case suggests that myelofibrosis may be a complication of PHO, especially in people with certain gene variants. The report is based on a single patient and a review of past medical literature. Because it is just one case, the findings are not proof that PHO causes myelofibrosis. More research is needed to understand the link. For now, doctors may consider checking blood counts in patients with PHO to catch any related problems early. This report adds to the growing understanding of rare genetic diseases and their possible complications.
Biallelic SLCO2A1 variants may be associated with myelofibrosis in patients with primary hypertrophic osteoarthropathyRare gene variants linked to bone disease and blood cancer
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This case report and review of literature describes a single patient with primary hypertrophic osteoarthropathy (PHO) who presented with fatigue, anemia, digital clubbing, and skin thickening. Whole-exome sequencing confirmed PHO via compound heterozygous variants in SLCO2A1 (c.940 + 1G>A and c.440G>A/p.Trp147*). The authors synthesize literature to suggest that myelofibrosis is a rare but significant complication of PHO, potentially occurring more frequently in patients with biallelic SLCO2A1 variants.
The study notes the limitations of a single case report and the associated review. While the findings highlight a potential genetic link between SLCO2A1 mutations and hematologic complications, the evidence is not sufficient to establish broad prevalence or definitive causality for all PHO patients.
Clinically, these results suggest that genetic testing and comprehensive hematologic evaluations may be useful tools in identifying related complications in patients diagnosed with PHO. However, practitioners should interpret these findings as preliminary due to the low certainty of a single case report.
How this fits prior evidence
This finding addresses a gap regarding the underlying mechanisms of primary hypertrophic osteoarthropathy (PHO) and its associated hematologic complications. While prior coverage has discussed management frameworks for myelofibrosis splenomegaly and specific treatments like azacytidin plus ruxolitinib in connective tissue disease with myelofibrosis, this report specifically links SLCO2A1 variants to the development of myelofibrosis in PHO patients.
Common questions
What is primary hypertrophic osteoarthropathy (PHO)?
PHO is a rare genetic condition that causes clubbing of the fingers, thickening of the skin, and bone problems. It is often linked to mutations in the SLCO2A1 gene.
What is myelofibrosis?
Myelofibrosis is a type of blood cancer that causes scarring in the bone marrow, leading to anemia, fatigue, and an enlarged spleen. It is a rare complication in this case.
How was the diagnosis made in this case?
The 45-year-old man had genetic testing called whole-exome sequencing, which found two mutations in the SLCO2A1 gene. This confirmed PHO and led to the discovery of myelofibrosis.
Should all PHO patients be tested for myelofibrosis?
This is a single case report, so it is not a recommendation for all patients. However, doctors may consider blood tests to monitor for complications in PHO patients.
More on Myelofibrosis
View Original Abstract ↓
Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
Real-world data confirms pembrolizumab offers long-term survival for advanced lung cancer patients
Related in Pulmonology & Critical Care
From Other Specialties
